Phaseline

Targets › ITGB3

ITGB3 (Integrin beta-3): drug programs, companies and trials

11 programs from 11 companies in 16 trials: 6 Phase 3, 4 Phase 1, 4 Phase 2, 2 Phase 4; Neurology, Oncology, Cardiovascular; next expected readout Dec 2026.

Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor (VWF). Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. (UniProt, P05106)

Open in Phaseline: the race on ITGB3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing Anzhen HospitalTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 4Acute Ischemic StrokeDec 2026
Second Affiliated Hospital of Soochow UniversityTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 4Mild StrokeFeb 2027
Beijing Tiantan HospitalY-4 tablets
Integrin alpha-IIb/beta-3 inhibitor
PDE3A, ITGB3, ITGA2B, IL1R1Phase 3Ischemic Stroke, Acute; Aneurysmal Subarachnoid Hemorrhage; Acute Ischemic Stroke; Stroke Acute …Dec 2026
General Hospital of Shenyang Military RegionTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3Stroke, IschemicSep 2027
Weifang Medical UniversityTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3Stroke, AcuteFeb 2029
Second Affiliated Hospital of Guangxi Medical UniversityTirofiban Hydrochloride
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3Acute Ischemic Stroke–
CeleCor TherapeuticsZalunfiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3ST-elevation Myocardial Infarction (STEMI)–
Erasmus Medical CentercRGD-ZW800-1
RGD peptide-based fluorescent tracer targeting αvβ3 integrin
ITGAV, ITGB3Phase 2Squamous Cell Carcinoma of the LarynxMar 2028
The First Affiliated Hospital of Xiamen University177Lu-AB-3PRGD2
Integrin αvβ3-targeting radioligand therapy (177Lu-labeled)
ITGAV, ITGB3Phase 1Refractory Solid TumorDec 2026
Memorial Sloan Kettering Cancer Centerfluorescent cRGDY-PEG-Cy5.5-C dots
RGD peptide-functionalized silica nanoparticles with fluorescent Cy5.5 dye for imaging int
ITGAV, ITGB3Phase 1Head and Neck MelanomaApr 2027
Peking Union Medical College Hospital68Ga-RGD
RGD peptide targeting integrin αvβ3 for PET imaging
ITGAV, ITGB3Phase 1KeloidOct 2027

Conditions

Acute Ischemic Stroke (3) Stroke Acute (2) Refractory Solid Tumor (1) Squamous Cell Carcinoma of the Larynx (1) Head and Neck Melanoma (1) ST-elevation Myocardial Infarction (STEMI) (1) Mild Stroke (1) Keloid (1) Stroke, Ischemic (1) Ischemic Stroke, Acute (1) Aneurysmal Subarachnoid Hemorrhage (1) Healthy Adult Male and Female Volunteers (1)

Modalities

small molecule (11)

Companies

The First Affiliated Hospital of Xiamen University (1) Erasmus Medical Center (1) Memorial Sloan Kettering Cancer Center (1) CeleCor Therapeutics (1) Second Affiliated Hospital of Soochow University (1) Peking Union Medical College Hospital (1) General Hospital of Shenyang Military Region (1) Beijing Tiantan Hospital (1) Second Affiliated Hospital of Guangxi Medical University (1) Beijing Anzhen Hospital (1) Weifang Medical University (1)

Related targets

ITGA2B (7) ITGAV (4) PDE3A (1) IL1R1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.